Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study

Annals of Oncology

Volumn 21, Issue 7, 2010, Pages 1552-1557

  Martin Broto, J ^a   Gutierrez, A ^a   Garcia del Muro, X ^b   Lopez Guerrero, J A ^c   Martinez Trufero, J ^d   de Sande, L M ^e   Lainez, N ^f   Maurel, J ^g   De Juan, A ^h   Losa, F ⁱ   Andres, R ^j   Casado, A ^k   Tejido, P G ^l   Blanco, R ^m   Carles, J ⁿ   Bellmunt, J ^o   Gomez Espana A ^p   Ramos, R ^a   Martinez Serra, J ^a   Llombart Bosch, A ^q   Poveda, A ^c   more..

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e Complejo Asistencial Universitario de León   (Spain)

^f Universidad Pública de Navarra   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ Hospital General   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL SAN PEDRO   (Spain)

^m HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁿ HOSPITAL DEL MAR   (Spain)

^o HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^p HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^q UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

KIT mutation; Localized GIST; Prognostic factors; Relapse free survival; Time dependence

Indexed keywords

GENE PRODUCT; PROTEIN KIT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANALYTICAL RESEARCH; ARTICLE; CANCER SURVIVAL; CHILD; CODON; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; GENETIC RISK; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CODON; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-KIT; SEQUENCE DELETION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954300616     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq047     Document Type: Article

References (29)

1. Demetri GD. OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease. Eur J Cancer 2003; 39(14): 1976-1977.
2. Emory TS, Sobin LH, Lukes L et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23(1): 82-87.
3. Aparicio T, Boige V, Sabourin JC et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004; 30(10): 1098-1103.
4. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33(5): 459-465.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23(2): 70-83.
6. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1): 51-58.
7. Lin SC, Huang MJ, Zeng CY et al. Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World J Gastroenterol 2003; 9(12): 2809-2812.
8. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103(4): 821-829.
9. Ahmed I, Welch NT, Parsons SL. Gastrointestinal stromal tumours (GIST)-17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol 2008; 34(4): 445-449.
10. Hassan I, You YN, Shyyan R et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 2008; 15(1): 52-59.
11. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472-480.
12. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): 1127-1134.
13. Ernst SI, Hubbs AE, Przygodzki RM et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78(12): 1633-1636.
14. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154(1): 53-60.
15. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59(17): 4297-4300.
16. Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20(18): 3898-3905.
17. Kim TW, Lee H, Kang YK et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10(9): 3076-3081.
18. Martin J, Poveda A, Llombart-Bosch A et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23(25): 6190-6198.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
21. Goh BK, Chow PK, Yap WM et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008; 15(8): 2153-2163.
22. Wardelmann E, Losen I, Hans V et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003; 106(6): 887-895.
23. Iesalnieks I, Rummele P, Dietmaier W et al. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 2005; 124(5): 740-748.
24. Tzen CY, Wang MN, Mau BL. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. Eur J Surg Oncol 2008; 34(5): 563-568.
25. Dematteo RP, Gold JS, Saran L et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112(3): 608-615.
26. Lewis JJ, Leung D, Casper ES et al. Multifactorial analysis of long-termfollow-up (more than 5 years) of primary extremity sarcoma. Arch Surg 1999; 134(2): 190-194.
27. Stojadinovic A, Leung DH, Allen P et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol 2002; 20(21): 4344-4352.
28. Engellau J, Anderson H, Rydholm A et al. Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Cancer 2004; 100(10): 2233-2239.
29. Bachet J-B, Hostein I, Le Cesne A et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer 2009; 101(1): 7-11.